89Bio通过提供库存资金,为肝脏和心肺疾病临床试验提供资金,筹集了125亿加元。 89bio raises $125M through stock offering to fund clinical trials for liver and cardiometabolic diseases.

生物制药公司89Bio已宣布提供1.25亿美元的公共库存,以资助其肝脏和心血管疾病临床试验。 Biopharmaceutical company 89bio has announced a $125 million public stock offering to fund its clinical trials for liver and cardiometabolic diseases. 该公司将发行约1 150万股,每股8.50美元,承保人可另外购买170万股。 The company will issue around 11.5 million shares at $8.50 each, with an option for underwriters to buy an additional 1.7 million shares. 收益将用于支持第3阶段对其主要药物候选者进行治疗肝病和高三甘酸盐的试验。 The proceeds will support Phase 3 trials for its lead drug candidate treating liver diseases and high triglycerides.